Literature DB >> 26983757

When two are better than one: bright phosphorescence from non-stereogenic dinuclear iridium(III) complexes.

Ruth E Daniels1, Stacey Culham1, Michael Hunter1, Marcus C Durrant1, Michael R Probert2, William Clegg2, J A Gareth Williams3, Valery N Kozhevnikov1.   

Abstract

A new family of eight dinuclear iridium(iii) complexes has been prepared, featuring 4,6-diarylpyrimidines L(y) as bis-N^C-coordinating bridging ligands. The metal ions are also coordinated by a terminal N^C^N-cyclometallating ligand L(X) based on 1,3-di(2-pyridyl)benzene, and by a monodentate chloride or cyanide. The general formula of the compounds is {IrL(X)Z}2L(y) (Z = Cl or CN). The family comprises examples with three different L(X) ligands and five different diarylpyrimidines L(y), of which four are diphenylpyrimidines and one is a dithienylpyrimidine. The requisite proligands have been synthesised via standard cross-coupling methodology. The synthesis of the complexes involves a two-step procedure, in which L(X)H is reacted with IrCl3·3H2O to form dinuclear complexes of the form [IrL(X)Cl(μ-Cl)]2, followed by treatment with the diarylpyrimidine L(y)H2. Crucially, each complex is formed as a single compound only: the strong trans influence of the metallated rings dictates the relative disposition of the ligands, whilst the use of symmetrically substituted tridentate ligands eliminates the possibility of Λ and Δ enantiomers that are obtained when bis-bidentate units are linked through bridging ligands. The crystal structure of one member of the family has been obtained using a synchrotron X-ray source. All of the complexes are very brightly luminescent, with emission maxima in solution varying over the range 517-572 nm, according to the identity of the ligands. The highest-energy emitter is the cyanide derivative whilst the lowest is the complex with the dithienylpyrimidine. The trends in both the absorption and emission energies as a function of ligand substituent have been rationalised accurately with the aid of TD-DFT calculations. The lowest-excited singlet and triplet levels correlate with the trend in the HOMO-LUMO gap. All the complexes have quantum yields that are close to unity and phosphorescence lifetimes - of the order of 500 ns - that are unusually short for complexes of such brightness. These impressive properties stem from an unusually high rate of radiative decay, possibly due to spin-orbit coupling pathways being facilitated by the second metal ion, and to low non-radiative decay rates that may be related to the rigidity of the dinuclear scaffold.

Entities:  

Year:  2016        PMID: 26983757     DOI: 10.1039/c6dt00881j

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  5 in total

1.  Quantum-chemical studies of homoleptic iridium(III) complexes in OLEDs: fac versus mer isomers.

Authors:  Izabela Grzelak; Bartosz Orwat; Ireneusz Kownacki; Marcin Hoffmann
Journal:  J Mol Model       Date:  2019-05-10       Impact factor: 1.810

2.  Multimetallic and Mixed Environment Iridium(III) Complexes: A Modular Approach to Luminescence Tuning Using a Host Platform.

Authors:  Victoria E Pritchard; Diego Rota Martir; Eli Zysman-Colman; Michaele J Hardie
Journal:  Chemistry       Date:  2017-05-03       Impact factor: 5.236

3.  An Unprecedented Family of Luminescent Iridium(III) Complexes Bearing a Six-Membered Chelated Tridentate C^N^C Ligand.

Authors:  Claus Hierlinger; Thierry Roisnel; David B Cordes; Alexandra M Z Slawin; Denis Jacquemin; Véronique Guerchais; Eli Zysman-Colman
Journal:  Inorg Chem       Date:  2017-04-10       Impact factor: 5.165

4.  Bis-cyclometalated iridium(iii) complexes with terpyridine analogues: syntheses, structures, spectroscopy and computational studies.

Authors:  Haleema Y Otaif; Samuel J Adams; Peter N Horton; Simon J Coles; Joseph M Beames; Simon J A Pope
Journal:  RSC Adv       Date:  2021-12-13       Impact factor: 4.036

5.  Pyridazine-bridged cationic diiridium complexes as potential dual-mode bioimaging probes.

Authors:  Ruth E Daniels; Luke K McKenzie; Jonathan R Shewring; Julia A Weinstein; Valery N Kozhevnikov; Helen E Bryant
Journal:  RSC Adv       Date:  2018-03-06       Impact factor: 3.361

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.